Novo Nordisk NYSE: NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
Name | Novo Nordisk |
Ticker | NVO |
Exchange | NYSE |
Sector | Health Care |
Industry | Diabetes |
Price
52W Low/High |
71.51
61.67 / 75.82 |
Momentum | Neutral |
Market cap | 169 B |
1Y Total Return |
18.33%
Weak |
1Y Volatility |
23.98%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novo Nordisk A/S is a global healthcare company engaged in diabetes care
Details
Ticker | NVO |
Name | Novo Nordisk |
ISIN | US6701002056 |
CUSIP | |
Exchange | NYSE |
Sector | Health Care |
Industry | Diabetes |
Country | Denmark |
Currency | U.S. Dollar |
Share as of 4/15/21
Close Price | 71.51 |
52W Low/High | 61.67 / 75.82 |
Market cap | 169 B |
1Y Total Return |
18.33%
Weak |
1Y Volatility |
23.98%
Low Risk |
Beta | 0.41 |
PE (trailing) |
24.22
Average |
12M Dividends | 0.213934 |
Last Dividend Date | 3/26/21 |
Dividend Yield | 0.30% |
Fin. Strength
Net Profit Margin | 33.2% |
Cash from Op. / Cur. Liabilities | 0.74 |
Diluted Earnings / Share | 2.95 |
ROE | 72.8% |
ROIC | 77.2% |
Price / Revenue | - |
Price / Book | - |
Price / CF | - |
Current Ratio | 0.9 |
Cur.Liabilities / Tot.Liabilities | 0.9 |
Financial Leverage | 0.16 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
20,811
|
18,212
|
17,152
|
18,010
|
15,822
|
17,224
|
|
Gross Profit |
17,379
|
15,214
|
14,450
|
15,167
|
13,390
|
14,641
|
|
R&D |
2,535
|
2,122
|
2,271
|
2,260
|
2,061
|
2,172
|
|
EBITDA |
10,083
|
8,688
|
8,174
|
8,609
|
7,320
|
8,377
|
|
Operating Income |
8,873
|
7,833
|
7,247
|
7,895
|
6,855
|
7,891
|
|
Net Income exc. Extra |
6,908
|
5,814
|
5,925
|
6,148
|
5,368
|
5,563
|
|
per Share | |||||||
Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
EPS exc. Extra |
2.95
|
2.44
|
2.44
|
2.48
|
2.12
|
2.16
|
|
Dividend |
0.21
|
0.15
|
0.16
|
0.18
|
0.20
|
0.09
|
|
Div. Yield (an.) |
1.87%
|
1.75%
|
2.27%
|
2.14%
|
3.93%
|
0.96%
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
23,758
|
18,748
|
16,989
|
16,504
|
13,806
|
14,650
|
|
Cash, Eq & Invt ShortTerm |
2,091
|
2,310
|
2,398
|
3,040
|
2,930
|
3,266
|
|
Total Current Assets |
10,788
|
9,322
|
9,059
|
9,687
|
8,459
|
8,800
|
|
Total Non-Current Assets |
12,969
|
9,426
|
7,930
|
6,816
|
5,346
|
5,850
|
|
Intangibles |
3,386
|
871
|
789
|
536
|
384
|
344
|
|
Total Liabilities |
13,377
|
10,152
|
9,038
|
8,471
|
7,398
|
7,154
|
|
Total Current Liabilities |
11,520
|
8,803
|
8,307
|
7,587
|
6,714
|
6,523
|
|
Long Term Debt |
1,856
|
1,349
|
731
|
884
|
684
|
632
|
|
Shareholder equity |
10,381
|
8,596
|
7,951
|
8,032
|
6,408
|
7,496
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
8,517
|
6,982
|
6,843
|
6,638
|
6,838
|
6,110
|
|
Depreciation |
943
|
845
|
602
|
513
|
452
|
472
|
|
Cash from Investing |
-3,678
|
-1,718
|
-1,853
|
-1,059
|
-961
|
-973
|
|
Capex |
954
|
1,333
|
1,476
|
1,228
|
999
|
831
|
|
Cash from Financing |
-5,286
|
-5,296
|
-5,295
|
-5,754
|
-5,504
|
-4,804
|
|
Stock Issued |
-2,763
|
-2,289
|
-2,388
|
-2,716
|
-2,131
|
-2,744
|
|
Debt (LT) Issued |
776
|
-111
|
14
|
0
|
0
|
0
|
|
Free Cash Flow |
8,558
|
6,050
|
6,460
|
5,272
|
5,079
|
5,382
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
33.2%
|
31.9%
|
34.5%
|
34.1%
|
33.9%
|
32.3%
|
|
NCFO / Op.Income |
96.0%
|
89.1%
|
94.4%
|
84.1%
|
99.8%
|
77.4%
|
|
Current Ratio |
0.9
|
1.1
|
1.1
|
1.3
|
1.3
|
1.3
|
|
Financial Leverage D/E |
0.16
|
0.08
|
0.01
|
0.03
|
0.01
|
0.02
|
|
Return on Capital Avg |
77.2%
|
90.6%
|
102.7%
|
117.4%
|
111.1%
|
117.4%
|
|
Return on Shareholder Equity |
72.8%
|
70.3%
|
74.1%
|
85.2%
|
77.2%
|
79.5%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available